As­traZeneca on emerg­ing mar­kets, GLP-1 plans and why it’s se­lec­tive about vac­cines

As­traZeneca put the spot­light on its near-20% rev­enue growth dur­ing first-quar­ter earn­ings, dri­ven in part by its suc­cess in emerg­ing mar­kets.

Ex­ec­u­tives on the com­pa­ny’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER